FDA Grants Priority Review to Avelumab for Urothelial Carcinoma

Share this content:
The FDA has granted Priority Review to the Biologics License Application for avelumab for the treatment of urothelial carcinoma.
The FDA has granted Priority Review to the Biologics License Application for avelumab for the treatment of urothelial carcinoma.

The U.S. Food and Drug Administration (FDA) has granted Priority Review to the Biologics License Application (BLA) for avelumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression on or after platinum-based chemotherapy, according to an announcement by EMD Serono and Pfizer.1

The BLA is based on preliminary data from the phase 1b JAVELIN Solid Tumor trial (ClinicalTrials.gov Identifier: NCT01772004), which evaluated the activity and safety of avelumab in 241 patients with metastatic urothelial carcinoma who progressed after platinum-based therapy or who were ineligible to receive cisplatin.

As of March 19, 2016, 17.6% (95% CI, 12.0-24.6) of the 153 evaluable patients achieved a confirmed objective response, including 9 complete and 18 partial responses. Nearly 90% of responses were ongoing, with the median duration of response not reached.

Median progression-free survival and overall survival were 6.4 weeks (95% CI, 6.1-11.4) and 7.0 months (95% CI, 5.6-11.1), respectively. The most common treatment-related adverse events were infusion-related reactions and fatigue.

RELATED: Urothelial Carcinoma: Year in Review

The FDA is expected to take action on this application by August 27, 2017.

Avelumab is an investigational, fully humanized PD-L1-blocking monoclonal antibody. In November 2016, the FDA granted Priority Review to the BLA for avelumab for the treatment of patients with metastatic Merkel cell carcinoma.

Reference

  1. FDA accepts the Biologics License Application for avelumab for the treatment of metastatic urothelial carcinoma for Priority Review [news release]. Rockland, MA: EMD Serono; February 28, 2017. http://media.emdserono.com/2017-02-28-FDA-Accepts-the-Biologics-License-Application-for-Avelumab-for-the-Treatment-of-Metastatic-Urothelial-Carcinoma-for-Priority-Review. Accessed February 28, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters